A study performed in T-ALL cell lines and treatment-resistant patient samples showed that BIM is repressed downstream of C-MYC activation, and that BIM upregulation and apoptosis could be restored by treatment with C-MYC or PI3K-AKT pathway inhibitors.62 A study performed in the colon cancer cell line, HCT116, showed that genes encoding the BH3-only proteins NOXA and BIM are direct targets of C-MYC. The gene discussed is BCL2L11; the disease is acute lymphoblastic leukemia.